Download

Select All

Download

CENTRAGARD® (eprinomectin and praziquantel transdermal solution)

PRODUCT OVERVIEW

CENTRAGARD® (eprinomectin and praziquantel transdermal solution) is indicated for the prevention of heartworm disease caused by Dirofilaria immitis, and for the treatment and control of roundworms (adult and fourth stage larval Toxocara cati), hookworms (adult and fourth stage larval Ancylostoma tubaeforme; adult Ancylostoma braziliense), and tapeworms (adult Dipylidium caninum and Echinococcus multilocularis) in cats and kittens 7 weeks of age and older and 1.8 lbs or greater.

CLINICAL BENEFITS

  • First feline product to combine eprinomectin & praziquantel

  • Broad-spectrum internal parasite protection, including prevention of heartworm disease and treatment and control of hookworms, roundworms, and tapeworms in cats.

  • Approved for cats and kittens as young as 7 weeks of age and weighing as little as 1.8 lbs

  • Easy-to-use, stress-free applicator

  • Flexible option for your practice. Convenient topical formulation that can safely be used monthly for year-round heartworm disease prevention and gastrointestinal parasite deworming OR as needed for treatment and control of specific parasite issues, such as hookworms, roundworms, and tapeworms, for your patients whose owners decline year-round heartworm disease protection.

DOSAGE & ADMINISTRATION

CENTRAGARD® (eprinomectin and praziquantel transdermal solution) is dosed at a minimum of 0.055 mL/lb (0.12 mL/kg), which delivers a minimum dose of 0.23 mg/lb eprinomectin and 4.55 mg/lb praziquantel. Administer the entire contents of a CENTRAGARD unit applicator topically once a month as specified in the following table:

 

Dosing Schedule

Image
Dosing Schedule for Centragard

 

To apply CENTRAGARD transdermal solution, pull back the plunger of the unit applicator slightly and remove the cap. Part the hair in one spot on the midline of the neck between the base of the skull and the shoulder blades, place the tip of the unit applicator on the skin and apply the contents directly on the skin. If the weight of the cat requires a second application, apply the contents in the same manner as described above in the same location.

SAFETY

Do not administer orally. Cats may salivate excessively and vomit if CENTRAGARD® (eprinomectin and praziquantel transdermal solution) is accidentally administered orally or is ingested through licking/grooming the application site. The safety of CENTRAGARD has not been tested in breeding, pregnant, or lactating cats.

 

IMPORTANT SAFETY INFORMATION: For topical use only. Side effects may include emesis, anorexia, lethargy, and hair changes and skin reactions at the site of application. If ingested, hypersalivation, vomiting and lethargy may be observed. The safety of CENTRAGARD has not been tested in kittens less than 7 weeks of age or less than 1.8 lbs. For more information, please see full prescribing information.

Trademarks

CENTRAGARD® and the Cat & Heart logo® are registered trademarks of Boehringer Ingelheim Animal Health France, used under license. ©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.

US-PET-0841-2020-V2
IMPORTANT SAFETY INFORMATION

CENTRAGARD® (eprinomectin and praziquantel transdermal solution) is for topical use on cats only. Side effects may include emesis, anorexia, lethargy, and hair changes and skin reactions at the site of application. If ingested, hypersalivation, vomiting, and lethargy may be observed. The safety of CENTRAGARD transdermal solution has not been tested in kittens less than 7 weeks of age or less than 1.8 lbs. For more information, please see full prescribing information.

Order Now

Log in to your BI-CONNECT™ account or create a new account to place an order.